Ирина Якутенко - Вирус, который сломал планету. Почему SARS-CoV-2 такой особенный и что нам с ним делать

«Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare», Folkh ä lsomyndighetens , 16-Jun-2020.

Лыскина Г. А., Бокерия О. Л., Сатюкова А. С., Ширинская О. Г., Леонтьева А. А. и Гагарина Н. В. Поражение коронарных артерий у детей с синдромом Кавасаки в Москве по данным 10-летнего наблюдения. XX Всероссийский съезд сердечно-сосудистых хирургов, 2014.

J. Toubiana et al. , «Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France», medRxiv , p. 2020.05.10.20097394, Jan. 2020.

C. Rosat Consiglio et al. , «The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19», medRxiv , p. 2020.07.08.20148353, Jan. 2020.

R. Wölfel et al. , «Virological assessment of hospitalized patients with COVID-2019», Nature , Apr. 2020.

C.-G. Huang et al. , «Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19», J. Clin. Microbiol. , vol. 58, no. 8, Jun. 2020.

T. C. Jones et al. , «An analysis of SARS-CoV-2 viral load by patient age», medRxiv , p. 2020.06.08.20125484, Jan. 2020.

«Children have a similar prevalence of COVID-19 antibodies to adults, but more than 99 % have mild symptoms», Sant Joan de Déu Barcelona , 09-Jun-2020.

«Första resultaten från pågående undersökning av antikroppar för covid-19-virus», Folkh ä lsomyndighetens , 18-May-2020.

«Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare», Folkh ä lsomyndighetens , 16-Jun-2020.

V. Moorthy, A. M. Henao Restrepo, M.-P. Preziosi, and S. Swaminathan, «Data sharing for novel coronavirus (COVID-19)», Bull. World Health Organ. , vol. 98, no. 3, pp. 150–150, Mar. 2020.

Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, «[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]»., Zhonghua Jie He He Hu Xi Za Zhi , vol. 43, no. 3, pp. 185–188, Mar. 2020.

«Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19, выпуск марта 2020 г»., ЛОМБАРДИЯ, SIMIT Итальянское Общество Инфекционных и Тропических болезней ОТДЕЛ РЕГИОНА . [Online]. Available: https://h-clinic.ru/upload/%D0%9D%D0%B5%D0%BE%D1%84%D0%B8%D1%86%D0%B8%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B8%CC%86%20%D0%BF%D0%B5%D1%80%D0%B5%D0%B2%D0%BE%D0%B4%20%D0%A0%D1%83%D0%BA%D0%BE%D0%B2%D0%BE%D0%B4%D1%81%D1%82%D0%B2%D0%B0%20%D0%BF%D0%BE%20%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8E%20%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2%20%D1%81%2 °COVID-19%20%D0%B2%20%D0%98%D1%82%D0%B0%D0%BB%D0%B8%D0%B8.pdf.

C. Mary, «Sound and Fury in the Microbiology Lab», Science, vol. 335, no. 6072, pp. 1033–1035, Mar. 2012.

«WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19», WHO , 04-Jul-2020.

P. Gautret et al. , «Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial», Int. J. Antimicrob. Agents , p. 105949, Mar. 2020.

P. Gautret et al. , «Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 8 °COVID-19 patients with at least a six-day follow up: A pilot observational study», Travel Med. Infect. Dis. , vol. 34, p. 101663, Mar. 2020.

Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020) // Министерство здравоохранения Российской Федерации, 2020. [Online]. Available: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf?fbclid=IwAR1p266v_Ok6Hw0Xjw5nRVtJopPRDKdpP1nEMDmDcvHl0ug9QZPo6-mV80c.

C. P. Skipper et al. , «Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19», Ann. Intern. Med. , pp. M20–4207, Jul. 2020.

N. W. Schluger, «The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale», Ann. Intern. Med. , pp. M20–5041, Jul. 2020.

FDA, «Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate», 2020.

M. R. Mehra, S. S. Desai, F. Ruschitzka, and A. N. Patel, «RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet , May 2020.

«Department of Error», Lancet , May 2020.

«Surgisphere: mass audit of papers linkgd to firm behind hydroxychloroquine Lancet study scandal», The Guardian , 10-Jun-2020.

J. Watson and et al., «Open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of‘Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis’. Lancet. 2020 May 22: S0140–6736(20)31180–6. doi: 10.1016/», 2020.

The Lancet Editors, «Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet , vol. 395, no. 10240, p. e102, Jun. 2020.

M. R. Mehra, F. Ruschitzka, and A. N. Patel, «Retraction — Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet , vol. 395, no. 10240, p. 1820, Jun. 2020.

M. R. Mehra, S. S. Desai, S. Kuy, T. D. Henry, and A. N. Patel, «Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19», N. Engl. J. Med. , vol. 382, no. 25, p. e102, Jun. 2020.

M. R. Mehra, S. S. Desai, S. Kuy, T. D. Henry, and A. N. Patel, «Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621»., N. Engl. J. Med. , vol. 382, no. 26, pp. 2582–2582, Jun. 2020.

P. Pradhan et al., «Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag», bioRxiv , p. 2020.01.30.927871, Jan. 2020.